Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Tivantinib Fails to Meet Primary Endpoint in PII Trial for Colorectal Cancer: Daiichi Sankyo
January 17, 2013
- Epadel Fails to Meet Endpoint in PII Trial with NASH Patients
January 16, 2013
- Eisai's Farletuzumab Fails to Meet Primary Endpoint in PIII Trial
January 16, 2013
- Otsuka Files for Approval for New Dry Powder Inhaler of Meptin
January 16, 2013
- GMP Violations at Drug Substance Makers Prompt Series of New Voluntary Recalls of Generics; Stable Supplies Disrupted
January 16, 2013
- Astellas and Sanwa Kagaku Launch Hyperkalemia Treatment Argamate Granule
January 15, 2013
- Different Reactions from Industry Following Announcement of Stricter Requirements on Sales of Epadel OTC
January 15, 2013
- Takeda Launches Hyperlipidemia Treatment Lotriga
January 11, 2013
- Eisai Ties Up with Epizyme, RMS to Develop a Companion Diagnostic
January 11, 2013
- Seiichiro Matsumura Serves as New President of Alcon Japan
January 11, 2013
- Nichi-Iko Voluntarily Recalls Picillibacta IV Inj. 1.5 g
January 11, 2013
- Takeda to Pitch Lotriga for Patients with Residual Event Risks, Cultivate New Market
January 10, 2013
- Janssen Resumes Supply of Doxil
January 10, 2013
- Daiichi Sankyo to Jointly Develop Autoimmune Disease Therapy with Amplimmune
January 10, 2013
- Top Officials of Major Drug Makers Express Concerns Mixed with Some Understanding About New Pricing Rule for Long-Listed Drugs
January 10, 2013
- BI, Eli Lilly Plan to Submit SGLT-2 Inhibitor Empagliflozin for Approval in Japan, US, and Europe in 2013
January 10, 2013
- Novartis Launches Respiratory Infection Treatment Tobi
January 10, 2013
- Chugai Licenses Novel Anticancer Agent FF284 to Debiopharm of Switzerland
January 10, 2013
- Pharmaceutical Firms’ Leaders Hopeful of New Products and Determined to Build Stronger Business Foundations
January 9, 2013
- AbbVie to Focus on Specialty Care, “Not Interested” in Established Markets: CEO Winer
January 9, 2013
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…